RESUMEN
BACKGROUND: Receptive vaginal penetration skills have been implicated in the etiology, explanatory models, and treatment of genito-pelvic pain penetration disorder (GPPPD). However, there are no psychometric skills measures designed to screen, assess, and stratify GPPPD. AIM: We aimed to develop and psychometrically evaluate a new scale-the Vaginal Penetration Skills Scale (VPSS)-to screen, assess, and stratify GPPPD. METHODS: This study included 148 Brazilian females with GPPPD symptoms (113 lifelong and 35 acquired) and 251 Brazilian females without sexual complaints. We conducted factor analyses considering all participants (n = 399). Then, we conducted latent class analysis within the GPPPD group to identify clusters of individuals with similar VPSS profiles. We assessed convergent validity through intercorrelation with the Brazilian versions of the Female Genital Self-Image Scale (FGSIS) and the 6-item Female Sexual Function Index (FSFI-6). OUTCOMES: We developed complete and short-form versions of the VPSS (VPSS-29 and VPSS-SF11, respectively), each with 3 dimensions, to screen, assess, and stratify GPPPD. RESULTS: Factor analysis yielded a 3-factor VPSS model with the "Nonsexual Genital Self-Exploration," "Nonsexual Vaginal Penetration Skills," and "Sexual Vaginal Penetration Skills" dimensions for both VPSS versions. The reliability was excellent for the VPSS-29 (ω = 0.981, α = 0.981) and the VPSS-SF11 (ω = 0.959, α = 0.961). All 3 dimensions could detect significant differences between patients with GPPPD and healthy females. They also differentiated the patients with GPPPD, distinguishing gradient levels. For convergent validity, we found moderate to strong correlations (rho = 0.715-0.745) between the VPSS, FGSIS, and FSFI-6. CLINICAL IMPLICATIONS: The VPSS can be applied easily in both clinical and research settings. STRENGTHS AND LIMITATIONS: The VPSS provides a concise and thorough evaluation of receptive vaginal penetration skills in both sexual and nonsexual contexts among patients with GPPPD. The sample had limited diversity regarding gender and sexual orientation; therefore, it is important to validate the use of this scale in populations beyond the cisgender heterosexual female population to ensure its applicability in diverse settings. CONCLUSION: These results support the reliability and psychometric validity of the VPSS as a self-report measure to screen, assess, and stratify GPPPD symptoms.
RESUMEN
Abstract Objective To comparatively evaluate the outcome of treatment with 150 versus 200 units (U) of botulinum toxin in achieving pain-free intercourse and relieving muscle contraction in order to allow gynecological examination. Methods In this comparative prospective observational study, 99 patients with vaginismus were treated with botulinum toxin injections from September 2016 to August 2021. Diagnosis and grading of vaginismus severity were assessed using a Female Sexual Function Index (FSFI) questionnaire. Under local or general anesthesia, botulinum toxin diluted with preservative-free saline (150 U and 200 U) was injected into, above, and below the right and left bulbospongiosus muscle and the lateral submucosal areas of the introitus and perineal body using an insulin syringe. Patients were recalled after 2 weeks, and the postoperative outcome was recorded using a similar preoperative questionnaire. Results Overall, the mean age of patients was 30.2 years. The baseline and clinical characteristics were comparable between the 2 groups (p > 0.05). Significant improvements were seen in the pain and anxiety scores of finger penetration, dilator use, intercourse, and cotton swab in individual groups. The intergroup comparisons between 150 U and 200 U of Botox were not statistically significant (p > 0.05). Conclusion Low-dose Botox (150 U) is equally effective as high dose Botox injections (200 U) in vaginismus patients. Therefore, Botox-150 U can be used to treat vaginismus as an alternative to high doses of the same substance.
Resumo Objetivo Avaliar comparativamente o resultado do tratamento com 150 versus 200 unidades (U) de toxina botulínica na obtenção de relações sexuais sem dor e no alívio da contração muscular para permitir o exame ginecológico. Métodos Neste estudo observacional prospectivo comparativo, 99 pacientes com vaginismo foram tratadas com injeções de toxina botulínica de setembro de 2016 a agosto de 2021. O diagnóstico e a classificação da gravidade do vaginismo foram avaliados usando um questionário Female Sexual Function Index (FSFI). Sob anestesia local ou geral, injetou-se toxina botulínica diluída em soro fisiológico sem conservantes (150 U e 200 U) nos músculos bulbo esponjoso direito e esquerdo e nas áreas submucosas laterais do intróito e corpo perineal, utilizando-se uma seringa de insulina. Os pacientes foram chamados após 2 semanas, e o resultado pós-operatório foi registrado usando um questionário pré-operatório semelhante. Resultados No geral, a média de idade dos pacientes foi de 30,2 anos. As características basais e clínicas foram comparáveis entre os 2 grupos (p > 0,05). Melhorias significativas foram observadas nos escores de dor e ansiedade à penetração com dedo, uso de dilatador, relação sexual e cotonete em grupos individuais. As comparações intergrupos entre 150 U e 200 U Botox foram não estatisticamente significativas (p > 0,05). Conclusão Botox de baixa dose (150 U) é tão eficaz quanto injeções de Botox de alta dose (200 U) em pacientes com vaginismo. Portanto, o Botox-150 U pode ser usado para tratar o vaginismo como alternativa às altas doses da mesma substância.
Asunto(s)
Humanos , Femenino , Ansiedad , Dolor/tratamiento farmacológico , Toxinas Botulínicas , VaginismoRESUMEN
Introducción: Dentro de los trastornos sexuales por dolor, se estudian la dispareunia y el vaginismo. El Manual diagnóstico y estadístico de los trastornos mentales V, los engloba bajo la categoría trastorno de dolor génito-pélvico y penetración. En Cuba, no existen muchos referentes teóricos de estas enfermedades. Objetivo: Sistematizar y actualizar los referentes teóricos relacionados con la dispareunia y el vaginismo, desde un enfoque sexológico. Métodos: Se realizó una revisión de la literatura publicada sobre el tema, de los últimos diez años, a texto completo, en las bases de datos SciELO y desde la búsqueda con Google académico con las palabras claves: trastornos sexuales por dolor, dispareunia y vaginismo. Desarrollo: La dispareunia y el vaginismo presentan una etiología multifactorial y variables grados de afectación del disfrute sexual de las parejas. Se presentan los aspectos esenciales de ambas entidades, fundamentalmente la clasificación, etiología, caracterización clínica, evaluación y el tratamiento. Conclusiones: La dispareunia y el vaginismo, son dos afecciones que afectan la vida sexual plena y satisfactoria y requieren de conocimientos, orientación y tratamiento especializado para que los resultados sean satisfactorios(AU)
Introduction: Within sexual disorders due to pain, dyspareunia and vaginismus are studied. The Diagnostic and Statistical Manual of Mental Disorders V encompasses them under the category of pelvic pain and penetration disorder. In Cuba, there are not many theoretical references of these diseases. Objective: Systematize and update the theoretical references related to dyspareunia and vaginismus, from a sexological approach Methods: A review of the literature published on the subject, of the last ten years, in full text, in the SciELO databases and from the search with academic Google with the keywords: sexual disorders due to pain, dyspareunia and vaginismus. Development: Dyspareunia and vaginismus have a multifactorial etiology and varying degrees of impairment of sexual enjoyment of couples. The essential aspects of both entities are presented, fundamentally the classification, etiology, clinical characterization, evaluation and treatment. Conclusions: Dyspareunia and vaginismus are two conditions that affect full and satisfactory sex life and require specialized knowledge, guidance and treatment for the results to be satisfactory(AU)